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Abstract
Background: While WHO recently recommended universal parasitological confirmation of suspected malaria prior to
treatment, debate has continued as to whether wide-scale use of rapid diagnostic tests (RDTs) can achieve this goal.
Adherence of health service personnel to RDT results has been poor in some settings, with little impact on anti-malarial
drug consumption. The Senegal national malaria control programme introduced universal parasite-based diagnosis using
malaria RDTs from late 2007 in all public health facilities. This paper assesses the impact of this programme on anti-malarial
drug consumption and disease reporting.
Methods and Findings: Nationally-collated programme data from 2007 to 2009 including malaria diagnostic outcomes,
prescription of artemisinin-based combination therapy (ACT) and consumption of RDTs in public health facilities, were
reviewed and compared. Against a marked seasonal variation in all-cause out-patient visits, non-malarial fever and
confirmed malaria, parasite-based diagnosis increased nationally from 3.9% of reported malaria-like febrile illness to 86.0%
over a 3 year period. The prescription of ACT dropped throughout this period from 72.9% of malaria-like febrile illness to
31.5%, reaching close equivalence to confirmed malaria (29.9% of 584873 suspect fever cases). An estimated 516576 courses
of inappropriate ACT prescription were averted.
Conclusions: The data indicate high adherence of anti-malarial prescribing practice to RDT results after an initial run-in
period. The large reduction in ACT consumption enabled by the move from symptom-based to parasite-based diagnosis
demonstrates that effective roll-out and use of malaria RDTs is achievable on a national scale through well planned and
structured implementation. While more detailed information on management of parasite-negative cases is required at point
of care level to assess overall cost-benefits to the health sector, considerable cost-savings were achieved in ACT
procurement. Programmes need to be allowed flexibility in management of these funds to address increases in other
programmatic costs that may accrue from improved diagnosis of febrile disease.
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Introduction
The World Health Organization recently strengthened its
recommendation for parasite-based diagnosis of malaria, extend-
ing it to all cases of suspected malaria prior to treatment with anti-
malarial medicines [1] Accurate diagnosis enables targeting of
anti-malarial drugs to those who will benefit, early identification of
non-malarial fever requiring alternative management, and accu-
rate and complete surveillance for confirmed malaria cases.
Reducing drug wastage, in addition to saving money and
conserving stocks of artemisinin-based combination therapies
(ACT), may prolong the usefulness of ACTs globally by reducing
pressure towards resistance. Clinical (symptom-based) diagnosis of
malaria has a very poor specificity [2,3,4], and microscopy is
predominantly limited to larger health facilities where the quality
of the result can be assured [5]. Provision of universal access to
parasite-based diagnosis for populations at risk of malaria will
therefore depend on the wide use of malaria rapid diagnostic tests
(RDTs); point-of care tests first introduced in 1993 (with the
ParaSight-F test) and with a proliferation of products now coming
into wide use [6,7,8,9].
Rapid point-of-care tests are routinely used for several diseases
including HIV and syphilis, replacing centralized laboratory
testing, as the requirement for a positive diagnostic result has
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18419long been accepted as a basis for treatment. , However, due to the
historical anomaly of wide use of poorly-targeted anti-malarial
treatment based on symptoms, particularly in sub-Saharan Africa,
the introduction of malaria point-of-care tests will lead to a
restriction in availability of treatment, rather than a widening of
access as is intended through the introduction of HIV and syphilis
test. Health care providers (and the communities they serve) must
now not only re-learn malaria diagnosis, but develop and
implement new management strategies for the majority of febrile
patients whose malaria test results will be negative. This poses a
dilemma for resource-limited health services, as diagnostics for
non-malarial febrile illness are often unavailable and management
strategies limited. Further, difficulties in ensuring malaria RDT
quality promoted doubt as to whether the RDT was sufficiently
accurate as a basis for with-holding a potentially life-saving anti-
malarial drug. The establishment of a product testing programme
[9], methods for laboratory-based RDT lot-testing [10], and
evidence of safe withholding of treatment in the field [11,12], have
addressed many of these concerns.
Although modeling suggests that malaria RDTs will be cost-
effective, and the potential public health advantages of enabling
early appropriate management for other causes of fever are clear,
these outcomes depend heavily on adherence to test results by
providers and patients and in access to effective management of
non-malarial fever [13,14]. Reported adherence to results has
varied in reported studies; some studies questioned whether RDT
use on a large scale can have a significant impact on the
management of febrile disease [15,16]. Successful implementation
will depend on a number of factors including good training of
health workers and modification of long-standing community and
clinician attitudes to the causes and management of febrile disease
[14,17,18,19].
While RDTs have been used on a large scale for several years in
some countries with anecdotal and unpublished health system data
suggesting an impact on anti-malarial therapy, these outcomes are
poorly documented and opinion on the advisability of wide-scale
use has remained divided [20,21]. Here we report the impact of
the comprehensive national roll-out of RDTs in Senegal, and its
impact on management of malaria in that country.
The Senegal Programme
Malaria is endemic throughout Senegal. Plasmodium falciparum
accounts for virtually all reported cases [22]. Approximately 75%
of patients access public health facilities for management of fever
[23], the vast majority doing so through peripheral health huts
(‘‘cases de sante ´’’) rather than hospitals or clinics with established
laboratory capacity. Artemisinin-based combination therapy
(ACT) was introduced as first-line therapy in 2006 (artesunate-
amodiaquine; AS-AQ). Until 2007 malaria diagnosis was pre-
dominantly based on clinical assessment, with microscopy-based
diagnosis limited to hospitals. Of 1555310 reported fever cases at
public health facilities in 2006, only 3.1% (48275) were confirmed
to be malaria by microscopy (Data records, Senegal National
Malaria Control Programme – NMCP).
From September 2007, the use of malaria RDTs was
incorporated by the NMCP into a revised national policy for
management of febrile illness. ACT was to be restricted to
confirmed malaria cases as RDTs became accessible. Implemen-
tation involved all public sector health facilities beyond hospital
level; 78 health centres, 1018 health posts and subsequently all
1640 health huts. This policy calls for the use of RDTs for
uncomplicated cases of fever without presence of other symptoms
suggestive of non-malarial aetiology. RDT-positive patients are to
be prescribed an antimalarial, and RDT-negative patients may be
prescribed broad spectrum antibiotics (trimethoprim-sulfamethox-
azole or amoxycillin) and antipyretics (Figure 1). Drug costs to the
patient were US$0.60 for an adult course and US$0.30 for a
paediatric course of antimalarials during the period covered by
this report (although antimalarials are now free of charge since
May 2010). Costs of antibiotics and antipyretics were US$0.60 and
US$0.20, respectively. Follow-up should occur after 48 hours to
confirm improvement or a need for referral (Figure 1). Cases
ineligible for an RDT (symptoms or signs of other aetiology) are to
be managed appropriately but tested with an RDT if still febrile
after 48 hours. Microscopy is reserved for complicated cases only
(e.g. severe cases or suspected treatment failures, usually after an
initial RDT-based diagnosis) [24]. RDT-based diagnosis is
provided free of charge to patients in public health facilities.
The introduction of malaria RDTs in 2007 was preceded by
scale-up of long-lasting bed-nets and indoor residual spraying
(IRS) (Table 1). The RDTs (Paracheck Device, Orchid Biomedical
Systems, India) were piloted on a limited scale by the national,
programme and the University of Cheikh Anta Diop (Laboratory
of Parasitology) in Dakar, during which training materials were
developed based on generic job-aids and training manuals
available from WHO [19,25]. This RDT met performance
criteria for WHO procurement recommendations in the WHO
product testing laboratory evaluation, and has demonstrated good
accuracy in the field in Senegal [9,26]. Health worker training in
case management and the Senegal national treatment guidelines
was conducted by district and regional management teams
developed by the NMCP and the University.
During the introduction of RDTs, the definition of ‘malaria-like
fever’ was formalized to improve targeting of RDTs(Figure 1) and a
vetting process put in place to verify accuracy of reporting and
collation of health information system data related to malaria,
including consumption data on ACT and RDTs. All malaria RDTs
are quality controlled after arrival in Senegal through lot-testing at
the Parasitology laboratory of the University of Anta Cheikh Diop
(Dakar) prior to dispersal to the field, based on the protocol of the
WHO Methods Manual [27]. Microscopy preparation follows the
Earl-Perez method described in the same Manual [10].
Methods
The evaluation is based on routinely-collected and collated
programme data, retrieved by the national malaria control
programme (Programme National de lutte contre le Paludisme)
and the Faculte ´d eM e ´decine, Universite ´ Cheikh Anta Diop de
Dakar in 2010. The national malaria surveillance system is based
on passive case detection. Data on suspected and laboratory
confirmed malaria cases, as well as data on consumption of anti-
malarial treatment are notified/reported monthly to the district
malaria programme by all levels of the public health system
(hospitals, health centres, health posts and health huts) using a
standard reporting form. At district level, the reported data is
entered into a database (Epi Info Version 6) and send to NMCP
on a monthly basis. The NMCP stipulates that the quality of
malaria surveillance data is assessed regularly at two levels of the
system: Firstly, supervisors from the district malaria programme
perform quarterly or bi-annual visits to health care facilities within
their district area to cross-check patient records at the facility with
data reported to the district from the facility; secondly, aggregated
data received from each district are reviewed by NMCP personnel,
regional and district malaria programme staff at quarterly
meetings.
For the purpose of this programme evaluation, the following
monthly data were extracted from the national malaria surveil-
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number of malaria-like febrile disease (‘suspected malaria’) cases,
defined as persons with fever (clinically determined or axillary
measured temperature $37.5uC; ii) number of persons tested for
malaria by microscopy or RDT; iii) number of malaria cases
confirmed by microscopy or RDT; iv) number of persons treated
with ACTs; and, v) total number of all-cause consultations.
We calculated the proportion of persons tested by RDT or
microscopy among all persons with suspected malaria and the
proportion of persons treated with ACT among all suspected
malaria cases in order to assess the impact of universal parasite-
based diagnosis using malaria RDTs on anti-malarial drug
consumption over a two-year period. The number of ACT
courses averted were estimated by subtracting the actual ACT
consumption in September 2007–December 2009 from the
predicted consumption derived from the proportion of malaria-
like fever cases treated with ACTs in January–August 2007 (prior
to RDT introduction).
Suspected malaria is reported here as recorded by the
programme, irrespective of tightening of the definition from late
2007 that was likely associated with re-training on RDT
introduction. The ‘confirmed malaria rate’ is derived from
reported confirmed malaria (microscopy-based) up to August
2007, and from the RDT positivity rate after this time, as most
microscopy performed after August 2007 involved referred cases
previously screened with RDTs. This avoids double-reporting of
such cases but will cause a small artefactual decline in late 2007,
and possibly a minor underestimation of case numbers thereafter,
but as microscopy was performed on only a small subset of patients
(5.2% of tested patients through 2009), any underestimation will
be small.
Results
In Senegal from 2007 to 2009, 2784532 suspected malaria cases
were reported at public health facilities. Case rates followed a clear
seasonal trend with an increase in suspected malaria from August
to December, accompanied by an increase in both parasite-
negative malaria-like febrile disease and in total consultations
unrelated to malaria-like fever over the same (wet season) months
(Figure 2). As the programme moved from predominantly
symptom-based treatment in 2007 to parasite-based treatment in
2009, the frequency of ACT use declined from 67.7% of the
malaria-like fever cases (suspected malaria) in 2007 to 31.5% in
Figure 1. Malaria Case Management Algorithm of the Senegal NMCP, introduced from July 2007.
doi:10.1371/journal.pone.0018419.g001
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malaria-like fever rose from 4.0% and 6.2% by microscopy and
RDT respectively in 2007 (RDTs having been introduced after
August), to 5.2% and 86.0% respectively in 2009, rising to 96% in
December of that year (Figure 2).
Throughout 2009, ACT consumption closely followed the
confirmed malaria rate (test-positive rate), apart from a marked
trough in ACT consumption in June corresponding with a
temporary stock-out in many clinics (Figure 3). During 2009,
174890 RDT-positive malaria cases were recorded and 184170
doses of ACT dispensed.
Table 2 summarizes diagnostic results and the corresponding
reduction in ACT courses dispensed and probable courses averted
from 2007 to 2009. Taking the period of 2007 prior to RDT
introduction (January to August) as a baseline, during which
72.9% of suspected malaria cases were treated with ACTs, the
estimated unnecessary ACT courses averted by the programme
rose to 249184 in 2009 (Table 2). An estimated 516576 courses of
ACT were averted over the entire 3 year period.
Discussion
These data demonstrate a significant decrease in reported
malaria cases on a national scale after implementation of parasite-
based diagnosis for malaria, with a corresponding reduction in
ACT consumption. Of similar importance, the introduction of the
strategy of universal diagnosis has provided a high degree of
certainty on malaria incidence throughout Senegal. This certainty
is enabling the national programme to accurately predict anti-
malarial drug requirements and creating the ability to concentrate
resources on areas of higher malaria burden and need, and to
assess the impact of future changes in intervention rates with
insecticide treated bednets and indoor residual spraying.
Prior to RDT introduction, microscopy was used in only a small
proportion of suspected malaria cases. Although the definition of
reported ‘malaria’ varied, the vast majority of reported cases were





Indoor residual spraying: primary vector
control intervention
1998
Insecticide-treated bednets (more recently
long-lasting nets)
2002
Intermittent prophylactic Therapy for
pregnancy (IPTp)
2004
Artemisinin-based combination therapy 2006
Rapid diagnostic tests (RDTs) 2007 (Sept)
RDT country ‘full coverage’ (roll-out to
health posts, then health huts)
2008 (Late)
doi:10.1371/journal.pone.0018419.t001
Figure 2. Evolution of parasite based diagnosis of malaria in Senegal public health services 2007–2009. A: Introduction of new case
definition for suspected malaria. B: Partial stock-out of ACT due to late replacement of expired stock in some clinics.
doi:10.1371/journal.pone.0018419.g002
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These figures for assumed malaria were the basis on which the
programme had forecast ACT consumption and base procure-
ment. With the introduction of RDTs, subsequent utilization of
ACTs was well below the predicted rate, and large stocks of ACTs
expired in mid-2009 (delays in replacement resulting in the
reported stock-out in some clinics, which accounts for the drop in
ACT consumption below the confirmed malaria rate at that time).
While the reported malaria-like fever rate remained high despite a
tightening of the clinical definition, the near-universal use of RDTs
in these cases has provided the national malaria control
programme with a solid basis for predicting drug consumption.
Senegal can now procure an appropriate quantity of ACTs - a
small proportion of the volume previously required. In 2009, the
Global Fund retained 1201764 Euros (,US$1.57) in unused funds
allocated for ACT procurement within the grant previously agreed
for the Senegal programme.
The reduction of ACT use to near-equivalence with the
confirmed malaria rate took some time. Obviously, the gradual
introduction of RDTs across the public health sector, necessitated
by the requirement to train health workers in RDT use, partly
explains this [19]. Eighteen months elapsed before ACT
consumption closely tracked the RDT-positive rate, by which
time RDT consumption had risen above 80% of the reported
malaria-like fever rate. Experience of poor compliance elsewhere
suggests that non-adherence to RDT results may also have been
responsible for the lag [15,16]. However, by mid-2008, high
adherence with diagnostic results was achieved and continues to
be sustained on a national scale.
The high adherence rate to RDT results is likely due to a
combination of factors. The Senegal programme, somewhat
unusually, charged patients diagnosed with malaria for first-line
anti-malarial drugs. While the cost to the consumer was small, this
is likely to have contributed to adherence to diagnostic results
Figure 3. Management of suspected malaria in Senegal public health services, 2007–2009.
doi:10.1371/journal.pone.0018419.g003


















Before introduction of RDTs Jan–Aug 2007 857179 33263 (3.9) 12468 (1.5) 624601 (72.9) N/A
After introduction of RDT s Sept–Dec 2007 605066 90313 (14.9) 40178 (6.6) 365740 (60.5) 75353
2008 737414 487188 (66.1) 217096 (29.4) 338335 (45.9) 199239
2009 584873 502739 (86.0) 174890 (29.9) 184170 (31.5) 241984
aTested by microscopy up to August 2007, and RDT only from September 2007. After August 2007, only RDTs became the first-line diagnostic test and microscopy was
confined to referral centres and results were likely to involve re-testing of a case. In 2009, 30414 cases were tested by microscopy.
bArtemisinin-based combination therapy.
cBased on treatment rate of malaria-like febrile disease (suspected malaria) in 2007 prior to rapid diagnostic test introduction.
doi:10.1371/journal.pone.0018419.t002
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higher than anti-malarial drugs, but only certain RDT-negative
patients were prescribed these (NMCP). Other major contributors
to adherence are likely to include: (1) a history of prioritizing
malaria diagnosis at a central and academic level in Senegal which
may have eased acceptance among planners and senior physicians,
despite the limited reach of microscopy [28]; (2) strong Ministry of
Health support for the programme, backed by policy change and
combined with a strong public sector (which is the first point of
access for most febrile patients) [23]; (3) tested training materials
and job-aids specifically adapted by the NMCP for use at the
district and community level [19]; a comprehensive supervisory
programme that maintains contact with peripheral health workers;
(4) an aggressive roll-out schedule sufficient to achieve near-
blanket national public-sector coverage in a relatively short time,
with RDT use thereby becoming the norm rather than confined to
certain clinics or regions; and (5) a quality assurance system based
on lot-testing of RDTs, capable of demonstrating that the
particular product used was working prior to deployment and
thereby at least partly allaying fears of false-negative results. The
University of Cheikh Anta Diop also actively collated and
disseminated data to community organizations and NGOs to
build public awareness of the change in national malaria policy
and guidelines, and engaged key opinion leaders to advocate for
RDT use.
While considerable cost savings have been achieved by the
Senegal NMCP by reducing unnecessary ACT procurement,
overall financial costs to the health service are unclear. Senegal’s
procurement costs per course of ACT (AS-AQ) averaged US$1.12
per course. As patients paid $0.60 and US$0.30 for adult and
paediatric courses of treatment respectively, the overall cost to the
programme, ignoring logistical costs, is approximately US$0.70.
Cost savings through reductions in ACT use will have been offset
by costs in RDTs (similar to the adult ACT course cost-to-
programme). Costs of antibiotics that can be provided to RDT-
negative patients are higher; full courses of amoxicillin and
cotrimoxazole cost the programme about US$2.00 and paracet-
amol US$1.00, while US$0.60 and US$0.20 is recouped from
patients. Figures on antibiotic dispensing prior to and after RDT
use were not available, but anecdotal evidence indicates that many
RDT-negative patients, probably appropriately, do not receive
them. While a limited evaluation in central Senegal indicated that
overall cost savings are likely to accrue [26], a full cost-benefit
analysis would need to take into account the likely benefit of earlier
appropriate management of non-malarial febrile illness where this
occurs, and the wider benefits of improved targeting of health
interventions enabled through the availability of more accurate
incidence data.
Modelling elsewhere suggests that an overall cost-benefit may be
expected when RDTs replace presumptive therapy, but these rely
on ACT costs higher than those of Senegal, and improved
management of non-malarial febrile illness is important to
achieving these benefits [13,29,30]. Other modelling and field
experience also suggests that overall cost implicaitons will be
relatively neutral [14,31], Through partial recoupment of
antibiotic costs from the consumer, the Senegal programme will
have limited the impact on less-well funded areas of the health
system that fund antibiotic prescription. However, funds saved on
ACT conservation could also be spent in future on support for
non-malarial fever management if more flexibility was allowed by
external agencies in the use of allocated funds.
Irrespective of financial loss or gain, the public health
imperative of not mis-leading patients or their carers into reliance
on an inappropriate three-day course of anti-malarial medication,
ineffective for their illness, is clear. Resultant delays in achieving a
correct diagnosis and appropriate management may increase
mortality from other potentially fatal or debilitating infections.
Mortality due to non-malarial febrile disease is twice that of
malaria globally, with malaria-endemic countries accounting for a
large proportion of this burden [32]. Thus, a basic public health
good is at issue, not just a possible benefit in terms of financial cost.
As malaria declines through much of sub-Saharan Africa [22],
the need to differentiate malaria from non-malarial fever becomes
more pressing. It is too early to confirm from the Senegal data
whether an overall decline in malaria is occurring, or whether the
apparent decline seen in Figure 2 reflects only better discrimina-
tion of malarial from non-malarial febrile illness, initially through a
tightening of clinical criteria and now by demonstration of
parasitaemia. Interestingly, the introduction of RDTs imposed
an additional burden on health workers on diagnosing ‘malaria-
like fever’; they now must perform a finger-prick and RDT prior
to further management and this may result in at least a sub-
conscious reduction in readiness to assign this diagnosis to febrile
patients. A decline in reported annual malaria deaths during this
period from 1935 to 722 indicates that any increased reluctance to
test for malaria was not resulting in poorer outcomes [22].
Alternatively, the downward trend in both non-malarial fever and
in confirmed malaria could be real, due to environmental changes
over this period affecting multiple pathogens or, speculatively, due
to reduced rates of malaria parasite carriage resulting in improved
health and resistance to other pathogens. RDT consumption
remains below the reported malaria-like fever rate, largely
accounted for by the incremental roll-out of RDTs to clinics, this
gap reducing toward the end of 2009 as RDT use reached 96% of
malaria-like fever cases (Figure 2). As ACT consumption ends
2009 marginally above the RDT-positive rate, these undiagnosed
cases are likely to account for much of the remaining over-
prescribing of ACT at this time.
The experience in Senegal demonstrates that parasite-based
diagnosis reliant on the use of malaria RDTs can be successfully
introduced on a national scale and dramatically reduce ACT
consumption. In the presence of a strong public health sector, and
possibly influenced by some financial incentive to the consumer,
RDTs have been used to transform the accuracy of malaria case
reporting and open new possibilities for addressing non-malarial
febrile illness and manage other causes of morbidity and mortality.
The ability to track the identify cases and track the impact of anti-
malarial interventions in this way through the widespread use of
parasite-based diagnosis will enable malaria elimination to be
seriously contemplated., but more flexibility is required in
management of funds saved from ACT procurement that will be
required to address increased programmatic costs in other areas.
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